GlassScriptPhysician profile
Bradley S Lair
NPI 1174584072
$603.29
in general payments reported to CMS, 2019-2025
16 companies · $16.30 in 2025
The $16.30 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121 · 2020: $125 · 2021: $52.19 · 2022: $132 · 2023: $74.33 · 2024: $82.37 · 2025: $16.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $137 · Education: $36.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $137.00 |
| Education | $36.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $142.17 | 2020-2023 | |
| Adaptive Biotechnologies Corporation | $116.93 | 2022 | |
| Janssen Biotech, INC. | $112.10 | 2019 | |
| Merck Sharp & Dohme LLC | $31.23 | 2024-2025 | Keytruda, Reblozyl, Welireg |
| Seagen INC. | $29.81 | 2021-2022 | |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Daiichi Sankyo INC. | $20.49 | 2024 | Injectafer |
| Astrazeneca Pharmaceuticals LP | $18.78 | 2023 | Imfinzi |
| Eisai INC. | $17.38 | 2023 | |
| Pharmaessentia USA Corporation | $17.29 | 2024 | Besremi |
| Aveo Pharmaceuticals, INC. | $15.00 | 2024 | |
| Tersera Therapeutics LLC | $14.66 | 2024 | Zoladex |
| Myriad Genetic Laboratories, INC. | $14.02 | 2021 | |
| Acrotech Biopharma INC. | $11.97 | 2021 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $8.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Lair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.